Copper deficiency is an uncommon cause of hematologic abnormalities in children that is often overlooked or misdiagnosed. Although cases have been reported because of malabsorption syndromes or after gastrointestinal surgeries, we report a case of copper deficiency-associated anemia and neutropenia in a child because of dietary restrictions, specifically, transitioning from a formula-based ketogenic diet to a pureed food-based ketogenic diet. On copper supplementation, the patient's anemia and neutropenia resolved. To our knowledge, this report is the first revealing copper deficiency anemia and neutropenia developing because of a ketogenic diet.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1542/peds.2017-3286 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database.
Ther Adv Drug Saf
January 2025
Department of Pharmacy, Daping Hospital, Army Medical University, No. 10 Changjiang Branch Road, Yuzhong District, Chongqing 400042, China.
Background: Gilteritinib and midostaurin are FLT3 inhibitors that have made significant progress in the treatment of acute myeloid leukemia. However, their real-world safety profile in a large sample population is incomplete.
Objectives: We aimed to provide a pharmacovigilance study of the adverse events (AEs) associated with gilteritinib and midostaurin through the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database.
Hematological toxicity assessment in breast cancer patients receiving paclitaxel: Retrospective study and single center experience.
Pak J Pharm Sci
January 2025
Clinical Pharmacy Department, Hiwa Cancer Hospital, Sulaymaniyah, Iraq.
Hematological toxicity is a predominant concern encountered during cancer treatment. Regular blood tests and follow-up are crucial for cancer patients. The objective of this study was to evaluate and compare the hematological toxicities seen by breast cancer patients who were administered paclitaxel during treatment cycles.
View Article and Find Full Text PDFEfficacy and Safety of Polatuzumab-Vedotin plus Bendamustine and Rituximab in patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Systematic Review and Meta-Analysis.
Crit Rev Oncol Hematol
January 2025
Liaquat National Hospital and Medical College, Karachi, Sindh, Pakistan. Electronic address:
Background: Diffuse large B-cell lymphoma (DLBCL), the most common non-Hodgkin's lymphoma subtype, relapses or becomes refractory (R/R) in 40% of cases after initial treatment. Among the second-line treatments for these patients is CAR T-cell therapy, which is considered the gold standard and treatment better than SCT. For these patients, polatuzumab vedotin in combination with bendamustine and rituximab (Pola-BR) is a novel treatment.
View Article and Find Full Text PDFA first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies.
Eur J Cancer
November 2024
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Purpose: MAK683, a first-in-class and highly selective allosteric inhibitor of the embryonic ectoderm development subunit of polycomb repressive complex 2, has shown sustained antitumor activity in tumor xenograft models. This first-in-human phase 1/2 study evaluated the safety, pharmacokinetics (PK), and clinical activity of single-agent MAK683 in advanced malignancies.
Methods: MAK683 was administered fasted once daily or twice daily continuously in 28-day treatment cycles.
[Identification of genetically determined chronic childhood cytopenia in the era of molecular medicine].
Orv Hetil
January 2025
1 Semmelweis Egyetem, Általános Orvostudományi Kar, Gyermekgyógyászati Klinika Budapest, Tűzoltó utca 7-9., 1094 Magyarország.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!